Sustained intraocular VEGF neutralization results in retinal neurodegeneration in the Ins2 Akita diabetic mouse

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Hombrebueno, Jose R ^a   Ali, Imran Ha ^a   Xu, Heping ^a   Chen, Mei ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INS2 PROTEIN, MOUSE; INSULIN; NEUTRALIZING ANTIBODY; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DEFICIENCY; DEGENERATIVE DISEASE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; GENETICS; METABOLISM; MOUSE; PATHOLOGY; RETINA NERVE CELL;

ANIMALS; ANTIBODIES, NEUTRALIZING; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; INSULIN; MICE; NEURODEGENERATIVE DISEASES; RETINAL NEURONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84950248415     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18316     Document Type: Article

References (56)

1. Klein, R., Klein, B. E., Moss, S. E., Davis, M. D. & DeMets, D. L. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102, 520-526 (1984).
2. Klein, B. E. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 14, 179-183 (2007).
3. Klein, R., Klein, B. E., Moss, S. E., Davis, M. D. & DeMets, D. L. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102, 527-532 (1984).
4. Diabetes, C. et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 169, 1307-1316 (2009).
5. Jyothi, S. & Sivaprasad, S. Five-year visual outcome following laser photocoagulation of diabetic macular oedema. Eye (Lond) 25, 851-858; quiz 859 (2011).
6. Evans, J. R., Michelessi, M. & Virgili, G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database Syst Rev 11, CD011234 (2014).
7. Baath, J., Ells, A. L., Crichton, A., Kherani, A. & Williams, R. G. Safety profile of intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther 23, 304-310 (2007).
8. Arevalo, J. F. & Garcia-Amaris, R. A. Intravitreal bevacizumab for diabetic retinopathy. Curr Diabetes Rev 5, 39-46 (2009).
9. Ozkiris, A. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema. Eye (Lond) 23, 616-620 (2009).
10. Velez-Montoya, R. et al. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Retina 29, 20-26 (2009).
11. Haritoglou, C. et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26, 999-1005 (2006).
12. Michaelides, M. et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 117, 1078-1086 e1072 (2010).
13. Hattori, T. et al. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy. Retina 30, 761-764 (2010).
14. Avery, R. L. et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113, 1695 e1691-1615 (2006).
15. Mason, J. O., 3rd, Nixon, P. A. & White, M. F. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 142, 685-688 (2006).
16. Zhang, X., Bao, S., Lai, D., Rapkins, R. W. & Gillies, M. C. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 57, 1026-1033 (2008).
17. Zhang, X., Zeng, H., Bao, S., Wang, N. & Gillies, M. C. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci 4, 27 (2014).
18. Ford, K. M., Saint-Geniez, M., Walshe, T., Zahr, A. & D'Amore, P. A. Expression and role of VEGF in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci 52, 9478-9487 (2011).
19. Ruiz de Almodovar, C., Lambrechts, D., Mazzone, M. & Carmeliet, P. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 89, 607-648 (2009).
20. Mackenzie, F. & Ruhrberg, C. Diverse roles for VEGF-A in the nervous system. Development 139, 1371-1380 (2012).
21. Saint-Geniez, M. et al. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One 3, e3554 (2008).
22. Kurihara, T., Westenskow, P. D., Bravo, S., Aguilar, E. & Friedlander, M. Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest 122, 4213-4217 (2012).
23. Nishijima, K. et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171, 53-67 (2007).
24. Rofagha, S. et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120, 2292-2299 (2013).
25. Park, H. Y., Kim, J. H. & Park, C. K. Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model. Am J Pathol 184, 1752-1762 (2014).
26. Yoshioka, M., Kayo, T., Ikeda, T. & Koizumi, A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 46, 887-894 (1997).
27. McLeod, D. Why cotton wool spots should not be regarded as retinal nerve fibre layer infarcts. Br J Ophthalmol 89, 229-237 (2005).
28. Schmidt, D. The mystery of cotton-wool spots-a review of recent and historical descriptions. Eur J Med Res 13, 231-266 (2008).
29. Brown, G. C. et al. Cotton-wool spots. Retina 5, 206-214 (1985).
30. Zeng, H. Y., Green, W. R. & Tso, M. O. Microglial activation in human diabetic retinopathy. Arch Ophthalmol 126, 227-232 (2008).
31. Pekny, M., Wilhelmsson, U. & Pekna, M. The dual role of astrocyte activation and reactive gliosis. Neurosci Lett 565, 30-38 (2014).
32. Romano, M. R. et al. Effects of bevacizumab on neuronal viability of retinal ganglion cells in rats. Brain Res 1478, 55-63 (2012).
33. Cheng, C. K. et al. Bevacizumab is not toxic to retinal ganglion cells after repeated intravitreal injection. Retina 29, 306-312 (2009).
34. Iriyama, A., Chen, Y. N., Tamaki, Y. & Yanagi, Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 91, 1230-1233 (2007).
35. Albert-Fort, M. et al. Retinal neurodegenerative changes in the adult insulin receptor substrate-2 deficient mouse. Exp Eye Res 124, 1-10 (2014).
36. Chen, M. et al. Age-and light-dependent development of localised retinal atrophy in CCL2(/)CX3CR1(GFP/GFP) mice. PLoS One 8, e61381 (2013).
37. Marc, R. E., Jones, B. W., Watt, C. B. & Strettoi, E. Neural remodeling in retinal degeneration. Prog Retin Eye Res 22, 607-655 (2003).
38. Kim, B. W. et al. Vascular endothelial growth factor (VEGF) signaling regulates hippocampal neurons by elevation of intracellular calcium and activation of calcium/calmodulin protein kinase II and mammalian target of rapamycin. Cell Signal 20, 714-725 (2008).
39. Park, S. H. et al. Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia 46, 1260-1268 (2003).
40. Szabadfi, K. et al. Protective effects of the neuropeptide PACAP in diabetic retinopathy. Cell Tissue Res 348, 37-46 (2012).
41. Hombrebueno, J. R., Chen, M., Penalva, R. G. & Xu, H. Loss of synaptic connectivity, particularly in second order neurons is a key feature of diabetic retinal neuropathy in the Ins2Akita mouse. PLoS One 9, e97970 (2014).
42. Roy, M. S., Gunkel, R. D. & Podgor, M. J. Color vision defects in early diabetic retinopathy. Arch Ophthalmol 104, 225-228 (1986).
43. Tregear, S. J., Knowles, P. J., Ripley, L. G. & Casswell, A. G. Chromatic-contrast threshold impairment in diabetes. Eye (Lond) 11(Pt 4), 537-546 (1997).
44. Kern, T. S. & Barber, A. J. Retinal ganglion cells in diabetes. Journal of Physiology-London 586, 4401-4408 (2008).
45. Lee, S. et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691-703 (2007).
46. Durham, J. T. & Herman, I. M. Microvascular modifications in diabetic retinopathy. Curr Diab Rep 11, 253-264 (2011).
47. Han, Z., Guo, J., Conley, S. M. & Naash, M. I. Retinal angiogenesis in the Ins2(Akita) mouse model of diabetic retinopathy. Invest Ophthalmol Vis Sci 54, 574-584 (2013).
48. Barber, A. J. et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 46, 2210-2218 (2005).
49. Hanhart, J. & Chowers, I. Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema. Case Rep Ophthalmol 6, 44-50 (2015).
50. Dabir, S. S. et al. Differential systemic gene expression profile in patients with diabetic macular edema: responders versus nonresponders to standard treatment. Indian J Ophthalmol 62, 66-73 (2014).
51. Hombrebueno, J. R., Luo, C., Guo, L., Chen, M. & Xu, H. Intravitreal Injection of Normal Saline Induces Retinal Degeneration in the C57BL/6J Mouse. Transl Vis Sci Technol 3, 3 (2014).
52. Luo, J. C., Toyoda, M. & Shibuya, M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 58, 2594-2600 (1998).
53. Paques, M. et al. Panretinal, high-resolution color photography of the mouse fundus. Invest Ophthalmol Vis Sci 48, 2769-2774 (2007).
54. Xu, H. et al. A clinical grading system for retinal inflammation in the chronic model of experimental autoimmune uveoretinitis using digital fundus images. Exp Eye Res 87, 319-326 (2008).
55. Hombrebueno, J. R. et al. Morphological changes of short-wavelength cones in the developing S334ter-3 transgenic rat. Brain Res 1321, 60-66 (2010).
56. Michael, I. P. et al. Local acting Sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye. EMBO Mol Med 6, 604-623 (2014).